{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:54:27Z","timestamp":1790643267884,"version":"4.1.0"},"reference-count":83,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Janus kinases inhibitors are molecules that target Janus kinases\u2014signal transducers and activators of transcription (JAK\/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases, including psoriasis. This process reduces psoriatic inflammation. The JAK inhibitors are divided into two generations. The first generation of JAK inhibitors blocks two or more different Janus kinases. The second generation is more specified and blocks only one type of Janus kinase and has less side effects than the first generation. Tofacitinib, ruxolitinib and baricitinib belong to first generation JAK inhibitors and decernotinib and filgotinib belong to second group. This narrative review summarizes the role of Janus kinase inhibitors in the therapy of psoriasis. Oral JAK inhibitors show promise for efficacy and safety in the treatment of psoriasis. Studies to date do not indicate that JAK inhibitors are superior to recent biologic drugs in terms of efficacy. However, JAK inhibitors, due to their lack of increased incidence of side effects compared to other biologic drugs, can be included in the psoriasis treatment algorithm because they are orally taken. Nevertheless, further studies are needed to evaluate long-term treatment effects with these drugs.<\/jats:p>","DOI":"10.3390\/jcm10194307","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T22:50:48Z","timestamp":1632351048000},"page":"4307","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Role of Janus Kinase Inhibitors in Therapy of Psoriasis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-9734","authenticated-orcid":false,"given":"Sylwia","family":"S\u0142uczanowska-G\u0142\u0105bowska","sequence":"first","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ziegler-Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-1630","authenticated-orcid":false,"given":"Kamila","family":"Szumilas","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-1208","authenticated-orcid":false,"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Di Meglio, P., Villanova, F., and Nestle, F.O. (2014). Psoriasis. Cold Spring Harb. Perspect. Med., 4.","DOI":"10.1101\/cshperspect.a015354"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","first-page":"Cd011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.39463","article-title":"Decernotinib: A Next-Generation Jakinib","volume":"68","author":"Gadina","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase Family in Autoimmune Skin Diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13555-019-0310-5","article-title":"Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience","volume":"9","author":"Huang","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4103\/idoj.IDOJ_474_18","article-title":"Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology","volume":"10","author":"Sonthalia","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: Biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging Topical and Systemic JAK Inhibitors in Dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.biocel.2009.09.004","article-title":"JAK3: A two-faced player in hematological disorders","volume":"41","author":"Cornejo","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic Treatment of Psoriasis with JAK Inhibitors: A Review","volume":"10","author":"Hansen","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_16","first-page":"4883","article-title":"The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice","volume":"20","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"283617","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: Treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","article-title":"The many faces of Janus kinase","volume":"83","author":"Seavey","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","article-title":"Selective Tyk2 inhibitors as potential therapeutic agents: A patent review (2015\u20132018)","volume":"29","author":"He","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease","volume":"44","author":"Liongue","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/leu.2015.218","article-title":"Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function","volume":"30","author":"Perner","year":"2016","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2017.08.040","article-title":"Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment","volume":"138","author":"Kim","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic alterations driving psoriasis pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3389\/fphar.2019.00872","article-title":"Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23\/17 Axis","volume":"10","author":"Sakkas","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_30","unstructured":"US Food and Drug Administration (2018, December 04). Xeljanz\u00ae Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jcph.1360","article-title":"Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning","volume":"59","author":"Purohit","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5414\/CP203516","article-title":"Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis","volume":"57","author":"Xie","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_33","unstructured":"US Department of Health and Human Services (2019, January 10). Clinical Pharmacology and Biopharmaceutics Review(s). Application Number: 203214Orig1s000, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/206089Orig1s000ClinPharmR.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","article-title":"Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2017.07.027","article-title":"Tofacitinib Is the Right OCTAVE for Ulcerative Colitis","volume":"153","author":"Pouillon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/PTT.S161453","article-title":"Tofacitinib in the management of active psoriatic arthritis: Patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: A Review in Rheumatoid Arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jcph.178","article-title":"Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease","volume":"54","author":"Krishnaswami","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of Pregnancies With Maternal\/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Callis Duffin, K., Bushmakin, A.G., Cappelleri, J.C., Mallbris, L., and Mamolo, C. (2019). A multi-item Physician Global Assessment scale to assess psoriasis disease severity: Validation based on four phase III tofacitinib studies. BMC Dermatol., 19.","DOI":"10.1186\/s12895-019-0088-2"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes Zoster in Patients Receiving JAK Inhibitors for Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_53","unstructured":"European Medicines Agency (2019, September 24). Restrictions in Use of Xeljanz While EMA Reviews Risk of Blood Clots in Lungs. Available online: https:\/\/regulatory-access.parexel.com\/news-and-press-releases\/restrictions-in-use-of-xeljanz-while-ema-reviews-risk-of-blood-clots-in-lungs-prac-17-05-2019."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bjd.12490","article-title":"Quantifying cardiovascular disease risk factors in patients with psoriasis: A meta-analysis","volume":"169","author":"Miller","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/ard.2010.142133","article-title":"Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives","volume":"70","author":"Kitas","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1874192401105010064","article-title":"Dyslipidaemia in rheumatological autoimmune diseases","volume":"5","author":"Toms","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1194\/jlr.M200440-JLR200","article-title":"A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers","volume":"44","author":"Hudgins","year":"2003","journal-title":"J. Lipid Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3899\/jrheum.160070","article-title":"Disease Activity and Increased Risk of Cardiovascular Death among Patients with Psoriatic Arthritis","volume":"43","author":"Juneblad","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: Implications for the rheumatologist","volume":"46","author":"Kaplan","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Wicker","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","article-title":"Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis","volume":"2","author":"Savage","year":"2015","journal-title":"Rheumatol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_70","unstructured":"US Food and Drug Administration (2019, April 15). Safety Trial Finds Risk of Blood Clots in the Lungs and Death with Higher Dose of Tofacitinib (Xeljanz, Xeljanz XR) in Rheumatoid Arthritis Patients; FDA to Investigate, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","article-title":"A novel treatment for psoriatic arthritis: Janus kinase inhibitors","volume":"133","author":"Chen","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/bmj.333.7564.380","article-title":"Psoriasis and its management","volume":"333","author":"Smith","year":"2006","journal-title":"BMJ"},{"key":"ref_78","first-page":"10","article-title":"Current guidelines for psoriasis treatment: A work in progress","volume":"101","author":"Golbari","year":"2018","journal-title":"Cutis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","article-title":"The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients","volume":"28","author":"Abrouk","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000478072","article-title":"Adverse Reactions to Biologics in Psoriasis","volume":"53","author":"Lockwood","year":"2018","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/19\/4307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:03:20Z","timestamp":1760166200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/19\/4307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":83,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10194307"],"URL":"https:\/\/doi.org\/10.3390\/jcm10194307","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}